NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: The Scott Partnership
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Prism Ideas Wins Queen’s Award for Enterprise 2010 - Prism Ideas, announced that it has been awarded a Queen’s Award for Enterprise 2010
Prism Ideas Wins Queen’s Award for Enterprise 2010

 

NewswireToday - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2010/04/22 - Prism Ideas, announced that it has been awarded a Queen’s Award for Enterprise 2010.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Prism Ideas, a leading independent provider of medical communications and drug development consultancy services, today announced that it has been awarded a Queen’s Award for Enterprise 2010 in the International Trade category for its outstanding growth in overseas markets. The award sees Prism recognised as one of the UK’s fastest growing international medical communications providers following a significant increase in export sales to international markets. Prism’s success has resulted in a remarkable 169% rise in the company’s overseas sales over the past three years.

The Queen’s Award for Enterprise is the most prestigious and widely recognised corporate accolade for UK industry. The International Trade category acknowledges companies that have demonstrated a major increase in overseas earnings. The award honors Prism’s phenomenal growth in the supply of its complete range of medical communications and drug development consultancy services to international markets.

Combining both commercial and clinical expertise, Prism’s unique range of drug development and medical communications services cover clinical programme consultancy, clinical trial support and medical marketing. Prism works from the conception of clinical plans, throughout the clinical evaluation phase and into post-marketing activities. Prism’s in-house scientific expertise, including specialist pharmaceutical physicians, enable the company to link research activities with the medical communications services necessary to achieve success for its clients.

Peter Cook, CEO and managing director of leading anti-infective drug development company, Biota comments, “I congratulate the whole team at Prism for this award in recognition of their outstanding growth over the past three years. As a Prism customer, the company offers us the expertise in clinical development and commercialisation crucial to helping us achieve our goals. I am confident that the company will continue to enjoy great success over the coming years and look forward to working with the team in the future.”

“Prism is delighted to have been selected for a Queen’s Award for Enterprise” comments Dr. James Sawyer MFPM, CEO of Prism. “The team has worked relentlessly to develop an innovative approach to exporting the company’s services to the international pharmaceutical industry and this is a real testament to the commitment of our employees and their thorough understanding of the industry. We have experienced tremendous growth over the past three years both in term of sales and locations, opening up a new office in Switzerland and with plans to expand to the U.S. this year. This independent and very prestigious endorsement of our achievements has instilled pride throughout the organisation.”

For further information about Prism Ideas, please call +44 (0) 1270 621 724

About Prism Ideas
Prism Ideas (prismideas.com) is an independent company providing drug development consultancy and expert medical affairs support to the pharmaceutical industry. The company offers a full range of medical communications services including congress materials, journal articles, publication plans, advisory boards and advocacy development; drug development consultancy and expert medical support throughout the clinical evaluation drugs from medical monitoring of early stage clinical studies through to post-marketing activities.

Prism’s knowledge of industry, together with a thorough understanding of the science, ensures that clinical trials and medical communications maintain the highest scientific quality whilst meeting the needs of the pharmaceutical industry.

Prism currently has offices in the UK and Switzerland with plans to open a U.S office during 2010.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Prism Ideas Wins Queen’s Award for Enterprise 2010

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Fiona Robinson - Scottpr.com 
+44(0)14 7753 9539 prism[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MONOVERSE USA, Inc.

Visit  The Franchise Group





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)